Osphena (ospemifene) has been approved by the FDA to treat dyspareunia. This is the first non-steroidal estrogen available for women with dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy (VVA) that is common during menopause.
Osphena (ospemifene), an estrogen agonist/antagonist with tissue selective effects, has been approved by the FDA to treat dyspareunia. This is the first non-steroidal estrogen available for women with dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy (VVA) that is common during menopause.
The results of a multicenter, randomized, double-blind, placebo-controlled trial and subsequent safety extension were published online and ahead of print in the journal Menopause. Researchers found that 60 mg of once-daily oral ospemifene was effective in treating of vulvar and vaginal atrophy in postmenopausal women with dyspareunia.1 The one-year, long-term safety extension study found no clinically significant adverse changes, including no clinically meaningful endometrial findings, no treatment-emergent adverse events of pelvic organ prolapse or venous thromboembolism, and no cases of endometrial hyperplasia or carcinoma.2 In both studies, hot flushes were the most common treatment-related adverse event.
1. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013 Jan 28. [Epub ahead of print].
2. Simon JA, Lin VH, Radovich C, Bachmann GA; The Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2012 Nov 8. [Epub ahead of print].
OASIS-1 trial reports reduced VMS frequency and severity from elinzanetant
May 17th 2024A recent study showcased at the 2024 ACOG Annual Clinical & Scientific Meeting unveils elinzanetant's efficacy in alleviating vasomotor symptoms, sleep disturbances, and enhancing menopause-related quality of life in postmenopausal women.
Read More
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Study links premature menopause to musculoskeletal pain and sarcopenia risks
May 1st 2024A recent study revealed an association between premature menopause and increased risks of musculoskeletal pain and sarcopenia, emphasizing the potential benefits of hormone therapy in mitigating long-term effects.
Read More
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More